- Home
- OMCL vs RCKT Comparison
OMCL vs RCKT Comparison
Compare OMCL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | RCKT |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 340.9M |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMCL | RCKT |
|---|---|---|
| Price | $43.86 | $3.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $43.00 | $29.12 |
| AVG Volume (30 Days) | 511.1K | ★ 2.3M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,177,740,000.00 | N/A |
| Revenue This Year | $8.61 | N/A |
| Revenue Next Year | $3.97 | N/A |
| P/E Ratio | $103.10 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $22.66 | $2.19 |
| 52 Week High | $47.69 | $13.50 |
Technical Indicators
Market Signals| Indicator | OMCL | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 74.57 | 52.07 |
| Support Level | $39.18 | $3.30 |
| Resistance Level | $45.36 | $3.65 |
| Average True Range (ATR) | 1.91 | 0.19 |
| MACD | 0.53 | 0.05 |
| Stochastic Oscillator | 85.53 | 66.22 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.